• Vaccine Name: Human cytomegalovirus DNA vaccine VCL-CB01 encoding phosphoprotein 65 and gB
• Target Pathogen: Human cytomegalovirus
• Vaccine Ontology ID: VO_0004341
• Type: DNA vaccine
• Status: Clinical trial
• Host Species as Laboratory Animal Model: Human
• Glycoprotein B gene engineering:
  • Type: DNA vaccine construction
  • Description: This DNA vaccine expressed the major hCMV surface glycoprotein B (Schleiss, 2009).
  • Detailed Gene Information: Click Here.
• UL83 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Human Response

• Vaccine Immune Response Type: VO_0000286
• Immune Response: VCL-CB01 increased T-cell responses compared with placebo (Schleiss, 2009).

Mouse Response

• Vaccine Immune Response Type: VO_0003057
• Efficacy: Preclinical investigation of the hCMV gB/pp65 DNA vaccine was initially conducted in mice. When formulated in PBS, lone gB and pp65 plasmids were highly immunogenic, but vaccination with the bivalent vaccine reduced immune responses to each antigen by 2.8- and 4-fold of the lone values, respectively. However, formulating the bivalent vaccine with 02A significantly (p = 0.048) increased the antigen-specific immune responses relative to those induced with the bivalent vaccine in PBS, as well as completely abrogating a decrease in pp65-specific T-cell responses (Schleiss, 2009).